D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 116 Citations 57,572 640 World Ranking 1834 National Ranking 1070

Overview

What is he best known for?

The fields of study he is best known for:

  • Cancer
  • Gene
  • Internal medicine

Ignacio I. Wistuba focuses on Lung cancer, Cancer research, Adenocarcinoma, Cancer and Pathology. His Lung cancer research incorporates elements of Carcinoma, Lung and Epidermal growth factor receptor. His study in Cancer research is interdisciplinary in nature, drawing from both Mutation, KRAS, Molecular biology and microRNA.

His Adenocarcinoma study integrates concerns from other disciplines, such as Carcinogenesis, Epithelial–mesenchymal transition, Small Cell Lung Carcinoma and Loss of heterozygosity. Ignacio I. Wistuba has included themes like Biomarker, Blockade and Bioinformatics in his Cancer study. His work investigates the relationship between Pathology and topics such as Cell that intersect with problems in Vimentin, Adenocarcinoma of the lung and Cell growth.

His most cited work include:

  • International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma (3017 citations)
  • Somatic mutations affect key pathways in lung adenocarcinoma (2148 citations)
  • Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers (1884 citations)

What are the main themes of his work throughout his whole career to date?

His main research concerns Lung cancer, Cancer research, Cancer, Internal medicine and Pathology. His Lung cancer study combines topics from a wide range of disciplines, such as KRAS, Carcinoma, Lung and Adenocarcinoma. The Cancer research study combines topics in areas such as Cell, Carcinogenesis, Cancer cell, Immune system and Metastasis.

His Cancer research includes themes of PI3K/AKT/mTOR pathway, Immunology and Bioinformatics. The study incorporates disciplines such as Gastroenterology and Oncology in addition to Internal medicine. His work carried out in the field of Oncology brings together such families of science as Stage and Biomarker.

He most often published in these fields:

  • Lung cancer (47.48%)
  • Cancer research (46.05%)
  • Cancer (29.93%)

What were the highlights of his more recent work (between 2018-2021)?

  • Cancer research (46.05%)
  • Lung cancer (47.48%)
  • Internal medicine (27.96%)

In recent papers he was focusing on the following fields of study:

Ignacio I. Wistuba mainly focuses on Cancer research, Lung cancer, Internal medicine, Oncology and Immune system. His work deals with themes such as Immune checkpoint, Immunotherapy, T cell and Adenocarcinoma, which intersect with Cancer research. His Adenocarcinoma research is multidisciplinary, incorporating perspectives in Carcinogenesis, Lung and Pathology.

His research in Lung cancer is mostly concerned with Non small cell. His Oncology study which covers Nivolumab that intersects with Ipilimumab. Ignacio I. Wistuba interconnects Computational biology and Disease in the investigation of issues within Cancer.

Between 2018 and 2021, his most popular works were:

  • Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer (183 citations)
  • Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical Trial. (137 citations)
  • Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer (80 citations)

In his most recent research, the most cited papers focused on:

  • Cancer
  • Gene
  • Internal medicine

His scientific interests lie mostly in Lung cancer, Cancer research, Internal medicine, Oncology and Immunotherapy. His study with Lung cancer involves better knowledge in Pathology. His biological study spans a wide range of topics, including Thyroid and Adenocarcinoma.

The study incorporates disciplines such as Cell, Cancer cell, T cell, Immune system and Metastasis in addition to Cancer research. His studies deal with areas such as Chemotherapy, Nivolumab, Atezolizumab, Immune checkpoint inhibitors and Major Pathologic Response as well as Oncology. His study in Immunotherapy is interdisciplinary in nature, drawing from both Immunohistochemistry and Targeted therapy.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma

William D Travis;Elisabeth Brambilla;Masayuki Noguchi;Andrew G Nicholson.
Journal of Thoracic Oncology (2011)

4675 Citations

Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers

Hisayuki Shigematsu;Hisayuki Shigematsu;Li Lin;Takao Takahashi;Masaharu Nomura.
Journal of the National Cancer Institute (2005)

2594 Citations

Somatic mutations affect key pathways in lung adenocarcinoma

Li Ding;Gad Getz;David A. Wheeler;Elaine R. Mardis.
Nature (2008)

2570 Citations

The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification

William D. Travis;Elisabeth Brambilla;Andrew G. Nicholson;Yasushi Yatabe.
Journal of Thoracic Oncology (2015)

2376 Citations

Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

Mark G. Kris;Bruce E. Johnson;Lynne D. Berry;David J. Kwiatkowski.
JAMA (2014)

1262 Citations

Characterizing the cancer genome in lung adenocarcinoma

Barbara A. Weir;Barbara A. Weir;Michele S. Woo;Gad Getz;Sven Perner;Sven Perner.
Nature (2007)

1179 Citations

An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Lauren Averett Byers;Lixia Diao;Jing Wang;Pierre Saintigny.
Clinical Cancer Research (2013)

906 Citations

The BATTLE Trial: Personalizing Therapy for Lung Cancer

Edward S. Kim;Roy S. Herbst;Ignacio Ivan Wistuba;Jiun-Kae Jack Lee.
Cancer Discovery (2011)

881 Citations

Somatic mutations of the HER2 kinase domain in lung adenocarcinomas

Hisayuki Shigematsu;Hisayuki Shigematsu;Takao Takahashi;Masaharu Nomura;Kuntal Majmudar.
Cancer Research (2005)

824 Citations

KRAS Mutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer

Erminia Massarelli;Marileila Varella-Garcia;Ximing Tang;Ana C. Xavier.
Clinical Cancer Research (2007)

824 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Ignacio I. Wistuba

John D. Minna

John D. Minna

The University of Texas Southwestern Medical Center

Publications: 190

Adi F. Gazdar

Adi F. Gazdar

The University of Texas Southwestern Medical Center

Publications: 176

Matthew Meyerson

Matthew Meyerson

Harvard University

Publications: 160

Ming-Sound Tsao

Ming-Sound Tsao

Princess Margaret Cancer Centre

Publications: 155

Pasi A. Jänne

Pasi A. Jänne

Harvard University

Publications: 145

William D. Travis

William D. Travis

Memorial Sloan Kettering Cancer Center

Publications: 131

Rafael Rosell

Rafael Rosell

Autonomous University of Barcelona

Publications: 112

Kwok-Kin Wong

Kwok-Kin Wong

New York University

Publications: 106

Mark G. Kris

Mark G. Kris

Memorial Sloan Kettering Cancer Center

Publications: 102

Yi-Long Wu

Yi-Long Wu

Guangdong Provincial People’s Hospital

Publications: 98

Tetsuya Mitsudomi

Tetsuya Mitsudomi

Kindai University

Publications: 94

John V. Heymach

John V. Heymach

The University of Texas MD Anderson Cancer Center

Publications: 93

Charles M. Rudin

Charles M. Rudin

Memorial Sloan Kettering Cancer Center

Publications: 89

Shinichi Toyooka

Shinichi Toyooka

Okayama University

Publications: 86

Marc Ladanyi

Marc Ladanyi

Memorial Sloan Kettering Cancer Center

Publications: 86

Gordon B. Mills

Gordon B. Mills

Oregon Health & Science University

Publications: 84

Trending Scientists

Márta Rencz

Márta Rencz

Budapest University of Technology and Economics

Joelle Pineau

Joelle Pineau

Facebook (United States)

Adrian C. Fisher

Adrian C. Fisher

University of Cambridge

Wolfgang Paul

Wolfgang Paul

Martin Luther University Halle-Wittenberg

Richard B. Silverman

Richard B. Silverman

Northwestern University

Kookrin Char

Kookrin Char

Seoul National University

Richard Karban

Richard Karban

University of California, Davis

Pil Joon Seo

Pil Joon Seo

Seoul National University

Fanghua Hao

Fanghua Hao

Beijing Normal University

Bo Thamdrup

Bo Thamdrup

University of Southern Denmark

Seog Bae Oh

Seog Bae Oh

Seoul National University

Peter Redgrave

Peter Redgrave

University of Sheffield

Ilan Goldenberg

Ilan Goldenberg

University of Rochester Medical Center

Monique Volman

Monique Volman

University of Amsterdam

Lois Bloom

Lois Bloom

Columbia University

Felicia Marie Knaul

Felicia Marie Knaul

University of Miami

Something went wrong. Please try again later.